der, years of experience, practice setting and number of pregnant patients with RD seen per month), their opinion on pregnancy in RD patients (pre-conception status of RD and counseling, remission length before allowing pregnancy) and compatible RD drugs with pregnancy and lactation. Qualitative variables were analyzed using Chi-square or Fisher's exact tests, while quantitative variables were analyzed using Wilcoxon or Student t tests. A total score of answers per physician in accordance with EULAR/BSR guidelines was calculated. Univariate and multivariate analysis assessed the variables significantly associated with this score. P value <0.05 indicated statistical significance.

Results: Thirty-nine (90.7%) rheumatologists participated in this survey. They had 22.2±11.6 years of practice. Ninety-four (41.4%) obstetricians participated in this survey. They had 26.0±12.8 years of practice. Figure 1 displays the percentage of physicians who consider the selected RD medications detrimental to/not compatible with fertility, pregnancy and breastfeeding. Average score of answers in accordance with EULAR/BSR guidelines was 0.654±0.154 and results were significantly different between specialties (p<0.001): rheumatologists scored between 0.41 and 1, with an average of 0.777±0.152 and obstetricians scored between 0.36 and 1 with an average of 0.603±0.124. Multivariable analysis showed that the scores reflecting adherence to recommendations were significantly associated with type of specialty (rheumatology v/s obstetrics) and number of pregnant patients with RD seen per month.

Conclusions: Advices given to RD patients who plan on becoming pregnant in Lebanon vary largely, especially among the physicians' specialty and experience in RD, which highlights the urgency of disseminating the EULAR/BSR guidelines among rheumatologists and obstetricians alike.

References:

- [1] Flint J et al, Rheumatology 2016.
- [2] Götestam Skorpen C et al, Ann Rheum Dis 2016.
- [3] Panchal S et al, Rheum Int 2013.
- [4] Ruiz-Irastorza G and Khamashta MA, ACR 2014.

Acknowledgements: Sponsor: Newbridge Pharmaceuticals. MW support: KBP-Biomark.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3430

AB0318 CLINICAL AND SEROLOGIC CHARACTERISTICS OF A COHORT OF ECUADORIAN MEN WITH RHEUMATOID ARTHRITIS

G. Maldonado¹, C. Ferro², R. Guerrero³, C. Paredes³, C. Rios⁴. ¹Universidad Espíritu Santo, ²Universidad Espíritu Santo, ³Universidad Católica Santiago de Guayaquil, ⁴Centro de Reumatología y Rehabilitación, Guayaquil, Ecuador

Background: Rheumatoid arthritis (RA) is an inflammatory and disabling disease whose expression and clinical course is influenced by gender. In developed countries the prevalence of RA is 0.5–1%, with a ratio 3:1 female:male. Comparative gender studies have shown that women have greater functional disability, disease activity and pain than men.

Objectives: The purpose of this study is to describe and compare the clinical and serological characteristics of a cohort of men with RA.

Methods: A cross-sectional study was conducted in patients with established diagnosis of RA (American College of Rheumatology criteria 1988) from the Luis Vernaza Hospital and a private rheumatology center (CERER). The data included clinical manifestations, demographic data, comorbidities, habits, treatment, activity index DAS28-CRP, HAQ-DI disability index and the PHQ-9 questionnaire. The statistical program SPSS V. 22 was used to analyze the data and calculate frequencies, percentages, means, ranges, Spearman correlation and ANOVA coefficient. Statistical significance used was 0.05, with a 95% reliability.

Results: A cohort of 50 men was compared with a control group of 50 women. Most men worked while women stayed at home (72% and 66%, respectively, p=0.000). Tobacco and alcohol were more common in men (34% vs 8% p=0.001 and 38% vs. 0% p=0.000 respectively). The delay in the first visit to the specialist was shorter in men than in women (24 vs 32 months) and they had a longer follow-up (55 vs 41 months). In clinical manifestations, women had greater fatigue (60% vs 30% p=0.003), weight loss (44% vs 20% p=0.010), loss of appetite (54% vs 12% p=0.000) and depression (60% vs 22% p=0.000). There was no significant difference in comorbidities and treatment between the groups. Men had lower disease activity: VSG (23 vs 47 p=0.046), DAS 28 (2.5 vs 3.4 p=0.011), HAQ DI (0.37 vs 1.12 p=0.000), functional disability (12% vs 36% p=0.005), severe disability (2% vs 22% p=0.002), painful joints (2 vs 8 p=0.000), swollen joints (2 vs 6 p=0.000) and VAS of doctor (2 vs 3 p=0.047).

Conclusions: This is the first cohort study of men with RA in Ecuador. As shown in other international studies 2–3, our results confirm that men have a less aggressive disease.

References:

- [1] Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. BioMed Central Ltd;2012;10(1):82.
- [2] Sokka T, Tozzo S, Cutolo M, Kautuainen H, Makinen H. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. Arthritis Res Ther. 2009;11(1):1–12.
- [3] Hallert E, Thyberg I, Hass U, Skargren E, Skogh T. Comparison between

women and men with recent onset rheumatoid arthritis of disease activity and functional ability over two years (the TIRA project). Ann Rheum Dis. 2003;62(7):667–70.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.1409

AB0319 COMORBIDITIES IN ECUADORIAN PATIENTS WITH RHEUMATOID ARTHRITIS

G. Maldonado¹, C. Rios², C. Ferro³, R. Guerrero⁴, C. Paredes⁴, M. Moreno⁵, C. Vallejo⁶. ¹Universidad Espíritu Santo, ²Universidad Espíritu Santo, ³Centro de Reumatología y Rehabilitación, ⁴Universidad Católica Santiago de Guayaquil, ⁵Universidad Espíritu Santo, ⁶Hospital Luis Vernaza, ⁶Sociedad Ecuatoriana de Reumatología, Guayaquil, Ecuador

Background: Rheumatoid arthritis (RA) is associated with several comorbidities that reduce life expectancy. These comorbidities may be due to the rheumatic process itself, treatment or be independent, and include: anemia, osteoporosis, fractures, infections, gastric ulcers, myocardial infarction, depression, lymphoma and other malignancies.

Objectives: The aim of this study is to determine the comorbidities in patients with an established diagnosis of rheumatoid arthritis.

Methods: A cross-sectional descriptive study was conducted in patients with an established diagnosis of RA according to the ACR 1987 criteria, from public and private rheumatology clinics in Guayaquil, Ecuador. The database included; demographics, comorbidities, habits, treatments, laboratory exams, number of swollen and tender joints, Visual Analog Scale (VAS), activity and disability index (DAS28 and HAQ-DI) and PHQ-9 for depression. The statistical program SPSS V. 22 was used to analyze the data and calculate frequencies, percentages, means, ranges, Spearman correlation and ANOVA coefficient. Statistical significance used was 0.05, with a 95% reliability.

Results: 402 patients with a mean age of 50 years were included, 87.8% (353) women and 12.2% (49) men. 93.8% (377) were mestizos, 3.5% (14) White, 1.5% (6) Indigenous and 1.2% (5) Afro-Ecuadorians. As for the marital status 55.5% (223) were married, 15.4% (62) cohabiting, 12.4% (50) divorced, 8.5% (34) singles and 8.2% (33) widowers. 9.7% (39) of the patients smoked, 7.5% (30) ingested alcohol and 0.5% (2) drugs. The average age of onset of the disease was 41 years, with a median time from onset of symptoms and the first rheumatology visit of 28.7 months, median follow-up time of 51.8 months and average disease duration of 11 years. For comorbidities, 54.8% (147/268) had dyslipidemia, 28.4% (114) gastric disease, 23.6% (95) hypertension, 20.1% (81) obesity, 19.6% (79) depression, 15.2% (61) thyroid disease, 12.4% (50) of the sexual involvement, 10.7% (43) allergies, 10.4% (32/307) hypertransaminasemia, 9.3% (21/225) anemia, and 6.7% (27) diabetes mellitus. 32.3% (114) of women have had at least one abortion. The PHQ-9 medium was 5.3; according to this 11.2% (45) corresponded to mild depression, 4.5% (18) moderate depression, 3.2% (13) moderately severe depression and 0.7% (3) severe depression. As for the other indicators of disease activity, the average for the number of painful joints was 5 (0–28), swollen joints 4 (0–26), patient VAS 3.9 (0–10) and doctor VAS 3.4 (0–10). In laboratory data, 67.4% (215/319) had positive ESR, 64.8% (149/230) PCR, 90.5% (182/201) anti CCP positive, and 94.4% (286/303) RF.

Conclusions: This is the first study of comorbidities in patients with RA in Ecuador. Patients with RA have a high prevalence of comorbidities and risk factors, which is why physicians should be prepared to prevent them and offer an early treatment.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.1408

AB0320 RHEUMATOID ARTHRITIS IN BRAZIL – THE “REAL” STUDY: A NATIONWIDE PROSPECTIVE STUDY

G. Castelar-Pinheiro¹, A.B. Vargas-Santos¹, C. Albuquerque², R. Amorim¹, R. Giorgi³, S. Radominski⁴, I. Pereira⁵, M.F. Guimarães⁶, M. Bértolo⁷, P. Louzada Jr.⁸, M.F. Cunha⁹, K. Bonfiglioli¹⁰, C. Brenol¹¹, L.M.H. Mota².

¹Internal Medicine, Rheumatology Unit, Universidade do Estado do Rio de Janeiro, Rio de Janeiro; ²Universidade de Brasília, Brasília; ³Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo; ⁴Universidade Federal do Paraná, Curitiba; ⁵Universidade Federal de Santa Catarina, Florianópolis; ⁶Universidade Federal de Minas Gerais, Belo Horizonte; ⁷Universidade Estadual de Campinas, Campinas; ⁸Universidade de São Paulo - Ribeirão Preto, Ribeirão Preto; ⁹Universidade Federal do Pará, Belém; ¹⁰Universidade de São Paulo, São Paulo; ¹¹Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Background: Early diagnosis and immediate treatment are critical in achieving optimal outcomes in rheumatoid arthritis (RA). However, anecdotal evidence suggests that in Brazil there is still a significant delay in patient referral, RA diagnosis and DMARD initiation. The lack of national data hinders effective advocacy for proper public health policies, which led the RA commission of the Brazilian Society of Rheumatology to create a nationally-representative multicenter RA cohort to provide the necessary data.

Objectives: To describe the development process and baseline characteristics of a large, nationally-representative multicenter cohort of RA patients in Brazil.

Methods: Eleven public rheumatology centers from all of the 5 regions of Brazil enrolled ~100 consecutive RA patients each (1987 ARA or 2010 ACR-EULAR). This cohort is being followed prospectively for 1 year, with systematic data collection at time 0, 6±1 months and 12±1 months, and registration of all other visits during this 1-year period. Data collection began in 08–2015, using a single online electronic medical record, and included demographic, socioeconomic, clinical, lab, radiographic and therapeutic characteristics, along with functional status, quality of life and adherence to treatment information.

Results: 1125 patients were enrolled (Table), ~90% were female, with a mean age of 56 years and median disease duration of 13 years. Median BMI was 27 kg/m², with 64% of the patients classified as overweight or obese. The interval between symptoms and diagnosis varied from 1 to 457 months (median 12 months). Almost half of the patients were on glucocorticoids, 96% on DMARDs, with 36% on biologics. Only 7% were seronegative for both rheumatoid factor and ACPA. Median HAQ-DI was 0.875 and median DAS28-ESR was 3.5, with 58.6% of patients presenting moderate or high disease activity.

Table 1. Patients baseline characteristics

	N	
Age, years*	1125	56.7 (22.1–88.8)
Female	1125	89.5%
Current or former smoker	1125	39.6%
BMI, kg/m ² *	1055	26.6 (15.8–56.2)
Disease duration, years*	1124	12.7 (0.7–56.7)
Rheumatoid factor+	1105	78.7%
ACPA+	479	76.8%
Erosive disease	1105	55.2%
Extra-articular manifestation ≥ 1	1118	23.3%
Drugs in use:		%
– Glucocorticoids	1125	47.0
– NSAIDs	1125	9.0
– Synthetic DMARDs	1125	90.8
– Methotrexate	1125	66.5
– Biologic DMARDs	1125	36.1
Erythrocyte sedimentation rate (ESR), mm/1st hour*	933	21 (1–140)
C-reactive protein, mg/dL*	954	0.7 (0–76.1)
DAS28-ESR*	932	3.5 (0.3–8.2)
HAQ-DI*	1121	0.875 (0–3)

*Results in median (range).

Conclusions: The delay in diagnosis may explain the high percentage of patients with moderate or high disease activity and erosive disease. The low level of physical dysfunction observed in this established, predominantly seropositive RA population may be explained by the large proportion of patients on glucocorticoid and biologic therapy. Our findings suggest that, despite current treatment concepts being well known and accepted by Brazilian rheumatologists, there is still a gap in early diagnosis and management of RA.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.1740

AB0321 RELATIONSHIP OF CAROTID FEMORAL PULSE WAVE VELOCITY WITH AGE AND TIME OF EVOLUTION IN PATIENTS WITH RHEUMATOID ARTHRITIS

C. Ramos¹, G. Alanis¹, D. Cardona², S. Totsuka¹, E. Cardona¹, F. Pérez¹, A. Coldivar¹, J. Gómez¹, M. Vázquez del Mercado¹. ¹Physiology, University of Guadalajara; ²Physiology, University of Guadalajara, Guadalajara, Mexico

Background: Early vascular aging occurring in Rheumatoid Arthritis (RA) may be a consequence of chronic inflammation. The measurement of Carotid-femoral pulse wave velocity (cfPWV) is the gold standard to evaluate arterial stiffness. Vascular aging is a result of a change in the biomechanical properties of the vascular wall. This process can be accelerated by the accumulated damage of high mechanical stress (high blood pressure), chronic inflammation and comorbidities such as smoking, Diabetes Mellitus and dyslipidemia¹.

Objectives: The aim of this study was to evaluate variations in the Carotid-Femoral Pulse Wave Velocity (cfPWV) and its association to age and time of disease evolution in patients with rheumatoid arthritis.

Methods: RA patients were matched for age and sex with healthy controls. Subjects with a history of smoking, cardiovascular disease, hypertension, diabetes mellitus, cancer, liver disease, thyroid disease and kidney disease were excluded. The cfPWV was calculated using the Pulse Pen[®] (Diatechne, Italy) device.

Results: We included 76 women with RA and 28 healthy women, mean age (44.3±10.92 vs. 43.0±16.26, P=0.654). cfPWV demonstrated good correlation with age (r=0.459, P<0.01), disease evolution time (r=0.311, P=0.008), triglycerides (r=0.289, P=0.03), total cholesterol (r=0.421, P<0.01) and atherogenic index (r=0.320, P=0.02). No association with disease activity was found. cfPWV was higher in those patients with RA >10 years evolution compared to patients with <10 years of disease evolution and to controls (P<0.05).

Conclusions: A significant association between cfPWV was seen in patients with RA, and was also correlated to age and to a disease evolution >10 years long without finding a significant association with increased disease activity.

References:

[1] -Kozakova M, Morizzo C, Guarino D, et al. The impact of age and risk factors

on carotid and carotid-femoral pulse wave velocity. Journal of hypertension 2015;33(7):1446–501 doi: 10.1097/HJH.0000000000000582 [published Online First: Epub Date].

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6405

AB0322 THE ROLE OF HOMA-IR AND HOMA-ISLET INDICES IN DIFFERENT CARBOHYDRATE METABOLISM DISORDERS DURING GLUCOCORTICOID THERAPY

G. Nurullina. Kazan Medical State University, KAZAN, Russian Federation

Background: Diabetogenic effect limits the use of glucocorticoids (GC), especially in patients with diabetes risk factors. At present HOMA index is widely used for the evaluation of insulin resistance (IR) and β -cell function. HOMA-IR index increase is an indirect measure of IR progression and cardiovascular risk elevation.

Objectives: To evaluate the role of modified HOMA-IR and HOMA-islet indices in different carbohydrate metabolism disorders (CMD) during oral (OGCT) and PULSE (GCPT) glucocorticoid therapy (GCT).

Methods: A prospective study including 118 patients with systemic lupus erythematosus (SLE) (n=63) and systemic vasculitis (SV) (n=55) was performed. Seventy one patients received GCPT (i.v. infusion of 10–15 mg/kg of prednisolone with 250 ml of normal saline per day, for 3 consecutive days (1 course of 3 sessions); course dose was 1800–3000 mg; 47 patients received oral GC 15–30 mg/day. HOMA-IR index and β -cell function (HOMA-islet index) were calculated as follows: HOMA-IR = 1.5 + fasting blood glucose (mmol/l) x fasting C-peptide level (pmol/l) / 2800. HOMA-islet = 0.27 x fasting C-peptide level (pmol/l) / (fasting blood glucose (mmol/l) – 3.5).

Results: GCPT was associated with less CMD compared to OGCT. Impaired fasting glucose (IFG) was observed in 7 (9.9%) and 9 (19.1%), impaired glucose tolerance (IGT) – in 9 (12.7%) and 14 (29.8%) and diabetes mellitus (DM) – in 9 (12.7%) and 13 (27.7%) patients in GCPT and OGCT groups, respectively. There was a significant decrease of HOMA-islet during glycemic peak in DM patients from 13.96 to 6.17 after GCPT (p<0.05), compared to insignificant changes in other groups. Decrease of HOMA-islet index reflects a disturbance of overall functional activity of β -cells in DM patients. After a course of GCPT HOMA-islet index was significantly lower in DM patients compared to patients with no CMD (11.8 vs. 15.4), as GCPT is associated with a decrease of β -cell function which does not return to baseline as a consequence of β -cell reserve depletion. No rapid decrease of β -cell function was observed in OGCT group, instead there was a compensatory increase, which was insufficient to maintain normoglycemia because of high insulin resistance. C-peptide, HOMA-IR and HOMA-islet levels in OGCT patients demonstrated the same trend as in GCPT patients. Significant differences were observed in patients with IGT and DM before and after oral glucose tolerance test (OGTT) on C-peptide (1042 pmol/l vs. 1978 pmol/l in IGT; 1306 pmol/l vs. 2286 pmol/l in DM) and HOMA-IR (4.53 vs. 9.81 in IGT; 5.6 vs. 11.27 in DM patients), whereas in patients without CMD and in patients with IFG, C-peptide before OGTT was 489 pmol/l vs. 743 pmol/l, after - 1295 pmol/l vs. 1488 pmol/l, HOMA-IR – 2.59 vs. 2.88 before OGTT and 2.88 vs. 5.85 after the test in the absence of CMD and in IFG patients, respectively. A significant decrease of β -cell function was observed in DM patients, reflected by a decrease of HOMA-islet index after OGTT compared to baseline (147 vs. 78.4).

Conclusions: Evaluation of blood glucose level, which was normal in all included patients, and isolated C-peptide evaluation are insufficient for the evaluation of carbohydrate metabolism before GCPT and long-term OGCT. The evaluation of modified HOMA-IR and HOMA-islet indices before the start of intensive GC treatment and during OGCT may improve early detection of risk groups for serious CMDs – IGT and DM.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5721

AB0323 CARBOHYDRATE METABOLISM AND GLUCOCORTICOID THERAPY IN PATIENTS WITH SYSTEMIC INFLAMMATORY DISEASES

G. Nurullina. Kazan Medical State University, Kazan, Russian Federation

Background: Glucocorticoid therapy (GCT) is one of the risk factors of carbohydrate metabolism disorders (CMD) in patients with systemic inflammatory diseases. CMD development is a concern not only with long-term therapy, but also during intensive short-term GC administration, which can lead to different CMDs, including impaired glucose tolerance (IGT) and diabetes mellitus (DM).

Objectives: to evaluate the prevalence of CMD after long-term and intensive GC treatment (GCT) in patients with systemic lupus erythematosus (SLE), systemic vasculitis (SV) and chronic glomerulonephritis (CGN).

Methods: Ninety eight patients with systemic inflammatory diseases were included (SLE - 53, SV - 35), among them 68 received GC pulse-therapy (GCPT) (1 series of 3 sessions), and 30 – oral GCT (OGCT). All patients underwent standard clinical and laboratory evaluation, oral glucose tolerance test (OGTT), evaluation of C-peptide, HOMA-IR and HOMA-islet indices.

Results: CMDs developed less often in patients receiving GCPT compared to long-term OGCT (p=0.035). In patients receiving OGCT the most prevalent CMDs were IGT and DM – in 9 (30.0%) and 8 (26.7%) patients respectively, which